Q1 2024 Aurobindo Pharma Ltd Earnings Call Transcript
Welcome to Aurobindo Pharma Q1 FY '24 Earnings Call. (Operator Instructions) Please note that this conference is being recorded.
I now hand the conference over to management for opening remarks. Thank you, and over to you.
Thank you, Anders. Good morning, and a warm welcome to our first quarter FY '24 earnings call. I'm Deepti Thakur from the Investor Relations team. We hope you have received the quarter 1 FY '24 financials and the press release that was sent out on Saturday. These are also available on our website.
I would now like to introduce my senior management team on the call with us, represented by Dr. Satakarni Makkapati, CEO of Aurobindo Biosimilars, Vaccines and Peptide businesses; Mr. Yugandhar Puvvala, CEO, Eugia Pharma Specialties Limited; Mr. S. Sanjeev Dani, COO and Head Formulations, Aurobindo Pharma Limited; Mr. Swami Iyer, CEO, Aurobindo Pharma USA; and Mr. S. Subramanian, CFO.
We will begin the call with the summary highlights from the management, followed by an interactive Q&A session. Please note
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |